Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...
Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has shared an announcement. On December 8, 2025, Structure Therapeutics announced positive ...
This research underscores the beneficial impact of the Medicaid Institution for Mental Diseases (IMD) exclusion waivers on psychiatric-specific and all-cause health care resource utilization and costs ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
Background The likelihood of HIV acquisition is increased following forced vaginal sex. This relates in part to ...
This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...
This study provides important evidence that negative affect is associated with slower cognitive processing in daily life, with findings replicated across three independent samples and supported by ...
There are nearly 300 data centers in Northern Virginia, scattered across Loudoun, Fairfax and Prince William counties. It's the largest concentration of data centers in the world. The increase in ...
The Indian Rupee slumps to its lowest level near 90.00 against the US Dollar amid continuous foreign outflow from the Indian equity market. India’s GDP growth surprisingly remained stronger at 8.2% in ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...